Drugmakers Struggle To Keep Up With Coronavirus Mutations

Bloomberg (11/16, Muller) reports, “Covid-19’s constant mutations have proven nearly impossible for drugmakers to keep up with.” The latest Omicron subvariants “threaten to render the last two antibody drugs on the market ineffective: Eli Lilly & Co.’s be...